Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case
A. O. Rasulov,
J. M. Madyarov,
A. E. Kulikov,
Z. R. Rasulov,
L. A. Shestakova,
D. A. Chekini,
E. K. Ibragimov,
E. N. Puchkova,
Yu. E. Lvova,
R. A. Rasulov https://doi.org/10.17650/2782-3202-2022-2-3-21-27
Abstract
Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhibitors (nivolumab) treatment for locally advanced MSI-H colon carcinoma with liver metastasis in 44-year-old patient resulted in tumor regression, so that R0 surgical procedure became possible. Computed tomography scan and pathology report showed complete response, in primary and metastatic tumors. As a result, this allowed to improve the quality of patient’s life.
About the Authors
A. O. Rasulov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
J. M. Madyarov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Jasur M. Madyarov
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. E. Kulikov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Z. R. Rasulov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
L. A. Shestakova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
D. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
E. K. Ibragimov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
E. N. Puchkova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Yu. E. Lvova
Centrosoyuz Hospital of the Russian Federation
Russian Federation
Russian Federation
Bld. 1, 39 Losinoostrovskaya St., Moscow 107150
R. A. Rasulov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Bld. 2, 8 Trubetskaya St., Moscow 119991
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
2. Al-Sukhni E., Attwood K., Mattson D.M. et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol 2016;23(4):1177–86. DOI: 10.1245/s10434-015-5017-y
3. Sidaway P. Neoadjuvant immunotherapy shows promise. Nat Rev Clin Oncol 2020;17(7):391. DOI: 10.1038/s41571-020-0372-4
4. Kanani A., Veen T., Søreide K. Neoadjuvant immunotherapy in primary and metastatic colorectal cancer. Br J Surg 2021;108(12):1417–25. DOI: 10.1093/bjs/znab342
5. Avalone A., Delrio P., Nasti G. et al. Preoperative nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study (NICOLE). Ann Oncol 2018;29(Suppl 8):viii150–204. DOI: 10.1093/annonc/mdy281.155
6. Chalabi M., Fanchi L.F., Dijkstra K.K. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–76. DOI: 10.1038/s41591-020-0805-8
7. Zhang X., Wu T., Cai X. et al. Neoadjuvant immunotherapy for MSI-H/ dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol 2022;13:795972. DOI: 10.3389/fimmu.2022.795972
8. Salvatore L., Bensi M., Corallo S. et al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA Study. J Clin Oncol 2021;39(15_suppl):3511. DOI: 10.1200/JCO.2021.39.15_suppl.3511
9. Yuki S., Bando H., Tsukada Y. et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020;38(15_suppl):4100. DOI: 10.1200/JCO.2020.38.15_suppl.4100
10. Cercek A., Lumish M., Sinopoli J. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363–76. DOI: 10.1056/NEJMoa2201445
11. Trojan J., Stintzing S., Haase O. et al. Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist 2021;26(12):e2110–e4. DOI: 10.1002/onco.13955
Review
For citations:
Rasulov A.O., Madyarov J.M., Kulikov A.E., Rasulov Z.R., Shestakova L.A., Chekini D.A., Ibragimov E.K., Puchkova E.N., Lvova Yu.E., Rasulov R.A. Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case. MD-Onco. 2022;2(3):21-27. (In Russ.) https://doi.org/10.17650/2782-3202-2022-2-3-21-27
Views:
300
Email this article 